Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Spleen Invigorating and Weight Reducing Decoction
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Traditional Chinese Medicine Treatment
1 trial -
Split dose of 4L PEG
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Health Behavior
1 trial -
Standard Dose Spirulina Platensis
Hospital Authority, Hong Kong
HBV Carrier
1 trial -
Standard clinical treatment
The First People's Hospital of Lianyungang
Acute Pancreatitis
1 trial -
Stapokibart
The First People's Hospital of Lianyungang
Primary Cutaneous Amyloidosis
1 trial -
Statin
Hospital Authority, Hong Kong
HCC
1 trial -
Stereotactic body radiotherapy (SBRT)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
HSCT
1 trial -
Study Product A (High-dose 2X)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hyperuricemia
1 trial -
Suanzaoren Decoction and Huanglian Wendan Decoction
The First People's Hospital of Lianyungang
Traditional Chinese Medicine
1 trial -
Subconjunctival dexamethasone and general anesthesia
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cataract
1 trial -
Sucrose Iron，subcutaneous recombinant human erythropoietin，intravenous vitamin C
The First People's Hospital of Lianyungang
Anemia
1 trial -
Sufentanil
The First People's Hospital of Lianyungang
Anesthesia
1 trial -
Sulfentanyl
The First People's Hospital of Lianyungang
Postoperative Nausea and Vomiting
1 trial -
Surgery combined with Target-reduction intensity-modulated radiotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Surgery-radiotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma
1 trial -
T cell injection targeting CD7 chimeric antigen receptor
The First People's Hospital of Lianyungang
T-ALL
1 trial -
T, 260 mg/m2, paclitaxel for injection (albumin-bound)
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
TCM+ Routine Therapy
The First People's Hospital of Lianyungang
Proteinuria
1 trial -
TEA plus GDMT
The First People's Hospital of Lianyungang
Heart Failure With Reduced Ejection Fraction
1 trial -
TNK plus standard medical treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Ischemic Stroke
1 trial -
TPO-RA
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Primary Immune Thrombocytopenic Purpura
1 trial -
TRT
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Tacrolimus or Cyclosporine A
The First People's Hospital of Lianyungang
Immune Tolerance
1 trial -
Tacrolimus+Mycophenolate mofetil
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lupus Nephritis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources